Major Depressive Disorder (DSM-V) – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)

The major depressive disorder (MDD) therapy market is crowded and highly genericized. Extensive use of generic agents—particularly selective serotonin reuptake inhibitors (SSRIs) as earlyline treatments—creates substantial barriers for new branded therapies. Brandonly products (e.g., Lundbeck/Takeda’s Trintellix/Brintellix; Lundbeck/Otsuka Pharmaceutical’s Rexulti/Rxulti; AbbVie’s Vraylar/Reagila; Axsome’s Auvelity; Johnson & Johnson Innovative Medicine’s Caplyta) primarily compete for use in treatmentrefractory patients. Johnson & Johnson Innovative Medicine’s Spravato offers a faster onset of therapeutic effect than currently approved therapies, addressing an important unmet need; however, its use in treatmentresistant depression remains limited by several constraints. Given the persistent unmet needs in MDD, physicians continue to look to emerging therapies—many of which feature novel mechanisms of action—as promising future options.

Questions answered

• What is the current size of the MDD therapy market in the major markets, and which key events will influence the market over the next decade?
• What is the epidemiology of MDD in the major markets? What percentage of prevalent patients are diagnosed and drug-treated?
• What factors drive and constrain the use of branded antidepressants and atypical antipsychotics in MDD? Which branded therapy is expected to experience the most commercial success during the forecast period?
• What are the greatest areas of unmet need in the treatment of MDD, and how are emerging therapies expected to address these unmet needs?

Content highlights

Geography: United States, EU5, Japan.

Primary research: Country-specific interviews with thought-leading psychiatrists; survey data collected for this and other Clarivate research

Epidemiology: Prevalence of MDD by country; diagnosed / drug-treated prevalence of MDD by country.

Forecast: 10-year, annualized, drug-level sales and patient share of key MDD therapies through 2035, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and emerging therapies.

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.